AbbVie Inc. (NYSE:ABBV) Is Largely Controlled by Institutional Shareholders Who Own 73% of the Company
AbbVie Hits 4-week High
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
モルガン・スタンレーはアッヴィ(ABBV.US)のレーティングを強気に据え置き、目標株価を224ドルに据え置いた
モルガン・スタンレーのアナリストTerence Flynnは$AbbVie(ABBV.US)$のレーティングを強気に据え置き、目標株価を224ドルに据え置いた。TipRanksのデータによると、このアナリストの最近1年間の的中率は49.6%、平均リターンは5.3%である。注 TipRanksは、金融アナリストの分析データと、アナリストの的中率および平均リターンに関する情報を提供している独立第三者で
AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call
经历2024年大丰收后,美国ETF或在今年遇挫
AbbVie (ABBV) Upgraded to Buy: What Does It Mean for the Stock?
Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet
Is AbbVie Inc. (ABBV) the Best Pharma Dividend Stock to Buy In 2024?
Trim the Mag 7 and Invest in Lower Valuation Dividend Growth Stocks – Miramar Capital
AbbVie's (NYSE:ABBV) Five-year Earnings Growth Trails the 20% YoY Shareholder Returns
Achievements and Progress Heading Into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
Looking Into AbbVie's Recent Short Interest
AbbVie (ABBV) Rises Yet Lags Behind Market: Some Facts Worth Knowing
$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
AbbVie (ABBV) Benefitted From Top-Line Growth From Its Immunosuppressive Drugs
Is AbbVie Stock a Buy?
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?